To provide an update to “Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012”. A consensus committee of 55 international experts representing 25 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. A stand-alone meeting was held for all panel members in December 2015. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development. The panel consisted of five sections: hemodynamics, infection, adjunctive therapies, metabolic, and ventilation. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles were generated. Each subgroup generated a list of questions, searched for best available evidence, and then followed the principles of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence from high to very low, and to formulate recommendations as strong or weak, or best practice statement when applicable. The Surviving Sepsis Guideline panel provided 93 statements on early management and resuscitation of patients with sepsis or septic shock. Overall, 32 were strong recommendations, 39 were weak recommendations, and 18 were best-practice statements. No recommendation was provided for four questions. Substantial agreement exists among a large cohort of international experts regarding many strong recommendations for the best care of patients with sepsis. Although a significant number of aspects of care have relatively weak support, evidence-based recommendations regarding the acute management of sepsis and septic shock are the foundation of improved outcomes for these critically ill patients with high mortality.

https://link.springer.com/content/pdf/10.1007%2Fs00134-017-4683-6.pdf

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Infectious Diseases Society of America.

http://caprockhematology.com/Site/AML_and_ALL_files/AML%20Review%20Blood%202010.pdf

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

An overview of the self-organizing map algorithm, on which the papers in this issue are based, is presented in this article.

The Self-Organizing Map

Cytomegalovirus infections following chemotherapies of the newer generation.

Acute lymphoblastic leukemia (ALL) represents the most frequent malignancy in children, and relapse/refractory (r/r) disease is difficult to treat, both in children and adults. In search for novel treatment options against r/r ALL, we studied inhibitor of apoptosis proteins (IAP) and Smac mimetics (SM). SM‐sensitized r/r ALL cells towards conventional chemotherapy, even upon resistance against SM alone. The combination of SM and chemotherapy‐induced cell death via caspases and PARP, but independent from cIAP‐1/2, RIPK1, TNFα or NF‐κB. Instead, XIAP was identified to mediate SM effects. Molecular manipulation of XIAP in vivo using microRNA‐30 flanked shRNA expression in cell lines and patient‐derived xenograft (PDX) models of r/r ALL mimicked SM effects and intermediate XIAP knockdown‐sensitized r/r ALL cells towards chemotherapy‐induced apoptosis. Interestingly, upon strong XIAP knockdown, PDX r/r ALL cells were outcompeted in vivo, even in the absence of chemotherapy. Our results indicate a yet unknown essential function of XIAP in r/r ALL and reveal XIAP as a promising therapeutic target for r/r ALL.

https://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202114557

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL

/pdf/vector-based-sars-cov-2-vaccination-is-associated-with-2ccrevsi.pdf

Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia

The present invention is related to a compound of formula (I) a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a metabolite thereof or a prodrug thereof; for use in a method for the treatment and/or prevention of cancer, wherein X is selected from the group consisting of N-R1, O and S; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkyl and hydrogen; R2 is selected from the group consisting of indolyl, substituted indolyl, azaindolyl and substituted azaindolyl; and R3 is selected from the group consisting of aryl, substituted aryl, unsubstituted heteroaryl, heterocyclyl and substituted heterocyclyl.

Use of maleimide derivatives for preventing and treating cancer

La presente invention concerne un compose de formule (I), un sel pharmaceutiquement acceptable de celui-ci, un hydrate de celui-ci, un solvate de celui-ci, un metabolite de celui-ci, ou un promedicament de celui-ci, destine a etre utilise dans un procede pour le traitement et/ou la prevention de la leucemie. Dans la formule (I) : X est choisi parmi le groupe constitue de N-R 1 , O et S; R 1 est choisi parmi le groupe constitue d'alkyle, de cycloalkyle, d'aryle, d'arylalkyle, et d'hydrogene ; R 2 est choisi parmi le groupe constitue d'indolyle, d'indolyle substitue, d'azaindolyle et d'azaindolyle substitue ; et R 3 est choisi parmi le groupe constitue d'aryle, d'aryle substitue, d'heteroaryle non substitue, d'heterocyclyle et d'heterocyclyle substitue.

Christian Junghanss

Papers

Cytomegalovirus infections following chemotherapies of the newer generation.

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL

Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia

Use of maleimide derivatives for preventing and treating cancer

Utilisation de dérivés de maléimide pour la prévention et le traitement de la leucémie